Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2023-04-21 Report Publication Anno…
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is a short press release dated April 21, 2023, announcing the company's management team's participation in an upcoming investor conference ('Van Lanschot Kempen Life Sciences Conference 2023' on April 25-26). It provides company background, contact information, and standard forward-looking statements/risk disclaimers. It is not a full financial report (10-K, IR), an earnings release (ER), or a transcript (CT). Since it is an announcement about future investor engagement and does not fit the specific categories like DIV, DIRS, or MANG, it falls best under the general category for regulatory announcements or investor relations updates that don't fit elsewhere. Given its nature as a brief update regarding investor events, it is classified as a Regulatory Filing (RNS) as a general announcement, although it could also be argued as a type of Investor Presentation announcement if the presentation itself was attached, but here it only announces attendance. Following the 'MENU VS MEAL' rule, this is an announcement, not the main report. RNS is the most appropriate fallback for general corporate news releases not covered by other specific codes.
2023-04-21 French
20-F/A
Annual Report FY 2022
2023-04-20 English
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2023-04-18 English
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly states its purpose in the title and opening paragraph: 'NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF APRIL 1, 2023' and references compliance with French regulations (Code de Commerce and AMF General Regulation) for releasing the total number of shares outstanding and voting rights. This type of mandatory disclosure regarding the total share count and voting power, often released monthly or quarterly, is a specific regulatory announcement. It is not a full Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). It most closely aligns with a mandatory regulatory disclosure concerning capital structure/shareholder rights, which fits best under the general 'Regulatory Filings' (RNS) category, as there is no specific code for 'Number of Shares Outstanding' disclosure, or potentially 'Declaration of Voting Results & Voting Rights Announcements' (DVA), although DVA usually refers to the *results* of a vote rather than the current share count basis for future votes. Given the context of mandatory disclosure based on regulatory articles (L. 233-8 II, 223-16), RNS is the most appropriate general regulatory filing fallback, although DVA is a close second if the focus is strictly on voting rights mechanics. Since this is a routine update of the share base used for voting rights calculations, RNS is chosen as the best fit among the provided options for a non-standard, mandatory regulatory update.
2023-04-18 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 1ER AVRIL 2023" (New number of shares and voting rights as of April 1, 2023). It explicitly states that it is published in accordance with French Commercial Code articles and AMF (Autorité des marchés financiers) regulations, detailing the total number of shares and voting rights as of a specific date. This type of mandatory disclosure regarding the total share capital and voting power is a specific regulatory filing requirement, often related to capital structure changes or mandatory periodic updates. While it touches upon capital structure, it is primarily a notification of the current share count, which aligns closely with announcements related to share capital changes or major shareholding notifications, but the most precise fit for a mandatory disclosure of the total number of shares and voting rights, especially when referencing AMF regulations for this specific purpose, is often categorized under general regulatory announcements or share capital updates. Given the options, 'Share Issue/Capital Change' (SHA) covers changes to the capital structure, and 'Major Shareholding Notification' (MRQ) covers changes in ownership thresholds. Since this is a periodic statement of the total count, it is a fundamental capital structure disclosure. However, the content is a direct notification of the total number of shares and voting rights, which is a specific type of regulatory disclosure. In many contexts, this specific type of filing (total shares/voting rights update) is often grouped under general regulatory filings (RNS) or capital structure updates (SHA). Since it is a formal, periodic disclosure mandated by the regulator (AMF) detailing the current state of the share base, and it is not an announcement of a transaction (POS) or a change in ownership threshold crossing (MRQ), it fits best as a general regulatory filing (RNS) or a capital structure update (SHA). Given the precise nature of the data (total shares and voting rights), it is a fundamental capital structure metric update. I will classify it as SHA as it directly relates to the composition of the capital, although RNS is a possibility if SHA is reserved for active issuance/buybacks. Since the document explicitly details the composition of the capital, SHA is the stronger fit over the general RNS fallback.
2023-04-18 French
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2023-04-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.